Epirium Bio is a biopharmaceutical company that has identified and established an IP-protected platform of orally bioavailable small molecules that constitute a new class of therapeutics with the potential to improve function in neuromuscular diseases, including sarcopenia and spinal muscular atrophy. We have generated preclinical data in a broader scope of indications with significant unmet medical need, including fibrosis, which our development pipeline has the potential to address.
Addressing Unmet Medical Need in Muscle Disease
Targeting PGE2 to enhance muscle function and promote muscle regeneration
- 4Optimal treatment modalitySmall molecule platform, leveraging multiple IP protected chemical scaffolds
- 3Broad clinical applicability “Best in Class” neuromuscular platform targeting indications with significant unmet needs
- 2Unique platform, significant competitive advantageStrong IP portfolio with “white space” therapeutic opportunity creating muscle rejuvenation and reversing muscle atrophy
- 1Novel MOA Inhibiting 15-PGDH, the enzyme inactivating PGE2, increases PGE2 to enhance muscle function and regeneration
